BlackRock, Inc. Reports 5.6% Ownership in Trevi Therapeutics, Inc.

BlackRock, Inc. has filed a Schedule 13G with the SEC, disclosing a 5.6% ownership stake in Trevi Therapeutics, Inc. as of September 30, 2025. The filing indicates that BlackRock beneficially owns 6,804,338 shares of Trevi Therapeutics' common stock, with sole voting power over 6,669,528 shares and sole dispositive power over all 6,804,338 shares. The filing also notes that no single person's interest in the common stock exceeds 5% of the total outstanding shares. The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc., on October 17, 2025.